RGC
RGC
KYG7487R1002
Regencell Bioscience Holdings L
Loading chart...

Company Profile

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Latest News

Is Regencell Bioscience Holdings (RGC) Fully Priced After Its Annual Loss Deepened?
RGC
RGCO
RGC Resources (RGCO) Q3 2026 Earnings Call Transcript
RGCO
RGCO
RGC Resources Q3 Earnings Call Highlights
RGCO
RGC Resources, Inc. Q3 2026 Earnings Call Summary
NVDARGCO

Related stocks

3320.HK
3320.HK • Hong Kong SAR China
CHINARES PHARMA
4.38 HKD
3.51B USD 1Y -11.9%
0867.HK
0867.HK • Hong Kong SAR China
CMS
10.54 HKD
3.27B USD 1Y -23.9%
HCM
HCM • Hong Kong SAR China
HUTCHMED (China) Limited
14.1 USD
2.45B USD 1Y -16.6%
HCM.L
HCM.L • Hong Kong SAR China
HUTCHMED (CHINA) LIMITED ORD US
203 GBp
2.33B USD 1Y -11.8%
0512.HK
0512.HK • Hong Kong SAR China
GRAND PHARMA
4.74 HKD
2.12B USD 1Y -43.5%
3933.HK
3933.HK • Hong Kong SAR China
UNITED LAB
7.52 HKD
1.89B USD 1Y -46.9%
688185.SS
688185.SS • China
CANSINO BIOLOGICS INC
98.46 CNY
3.64B USD 1Y +25.7%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics
Country
Hong Kong SAR China
Region
Asia-Pacific
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.regencellbioscience.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
276.6% p.a.
Max Drawdown (5Y)
-93.9%
Sharpe Ratio (5Y)
0.25
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (349.8%) is noticeably higher than the 5Y average (276.6%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (276.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -93.9% in the extended horizon.
ende